114 related articles for article (PubMed ID: 38279448)
1. KIAA0101 promotes cisplatin resistance through regulating cell apoptosis in lung cancer cells.
Zhang C; Liu Y; Zhao J; Xu J; Pei B; Liu X; Yue X
Cell Mol Biol (Noisy-le-grand); 2023 Dec; 69(14):172-176. PubMed ID: 38279448
[TBL] [Abstract][Full Text] [Related]
2. Downregulation of Meg3 enhances cisplatin resistance of lung cancer cells through activation of the WNT/β-catenin signaling pathway.
Xia Y; He Z; Liu B; Wang P; Chen Y
Mol Med Rep; 2015 Sep; 12(3):4530-4537. PubMed ID: 26059239
[TBL] [Abstract][Full Text] [Related]
3. ZCCHC10 suppresses lung cancer progression and cisplatin resistance by attenuating MDM2-mediated p53 ubiquitination and degradation.
Ning Y; Hui N; Qing B; Zhuo Y; Sun W; Du Y; Liu S; Liu K; Zhou J
Cell Death Dis; 2019 May; 10(6):414. PubMed ID: 31138778
[TBL] [Abstract][Full Text] [Related]
4. WP1130 attenuates cisplatin resistance by decreasing P53 expression in non-small cell lung carcinomas.
Wang X; Bao Y; Dong Z; Chen Q; Guo H; Ziang C; Shao J
Oncotarget; 2017 Jul; 8(30):49033-49043. PubMed ID: 28446729
[TBL] [Abstract][Full Text] [Related]
5. Long non‑coding RNA AK001796 contributes to cisplatin resistance of non‑small cell lung cancer.
Liu B; Pan CF; Ma T; Wang J; Yao GL; Wei K; Chen YJ
Mol Med Rep; 2017 Oct; 16(4):4107-4112. PubMed ID: 29067469
[TBL] [Abstract][Full Text] [Related]
6. Variant 1 of KIAA0101, overexpressed in hepatocellular carcinoma, prevents doxorubicin-induced apoptosis by inhibiting p53 activation.
Liu L; Chen X; Xie S; Zhang C; Qiu Z; Zhu F
Hepatology; 2012 Nov; 56(5):1760-9. PubMed ID: 22576474
[TBL] [Abstract][Full Text] [Related]
7. Cisplatin resistance in non-small cell lung cancer cells is associated with an abrogation of cisplatin-induced G2/M cell cycle arrest.
Sarin N; Engel F; Kalayda GV; Mannewitz M; Cinatl J; Rothweiler F; Michaelis M; Saafan H; Ritter CA; Jaehde U; Frötschl R
PLoS One; 2017; 12(7):e0181081. PubMed ID: 28746345
[TBL] [Abstract][Full Text] [Related]
8. Expression of KIAA0101 protein is associated with poor survival of esophageal cancer patients and resistance to cisplatin treatment in vitro.
Cheng Y; Li K; Diao D; Zhu K; Shi L; Zhang H; Yuan D; Guo Q; Wu X; Liu D; Dang C
Lab Invest; 2013 Dec; 93(12):1276-87. PubMed ID: 24145239
[TBL] [Abstract][Full Text] [Related]
9. MiR-192/NKRF axis confers lung cancer cell chemoresistance to cisplatin via the NF-κB pathway.
Li Y; Zu L; Wu H; Zhang F; Fan Y; Pan H; Du X; Guo F; Zhou Q
Thorac Cancer; 2022 Feb; 13(3):430-441. PubMed ID: 34953057
[TBL] [Abstract][Full Text] [Related]
10. Downregulation of basic fibroblast growth factor increases cisplatin sensitivity in A549 non-small cell lung cancer cells.
He L; Meng Y; Zhang Z; Liu Y; Wang X
J Cancer Res Ther; 2018; 14(7):1519-1524. PubMed ID: 30589033
[TBL] [Abstract][Full Text] [Related]
11. Proteomics reveals a therapeutic vulnerability via the combined blockade of APE1 and autophagy in lung cancer A549 cells.
Pan ST; Zhou J; Yang F; Zhou SF; Ren T
BMC Cancer; 2020 Jul; 20(1):634. PubMed ID: 32641008
[TBL] [Abstract][Full Text] [Related]
12. Mutant p53 confers chemoresistance in non-small cell lung cancer by upregulating Nrf2.
Tung MC; Lin PL; Wang YC; He TY; Lee MC; Yeh SD; Chen CY; Lee H
Oncotarget; 2015 Dec; 6(39):41692-705. PubMed ID: 26497680
[TBL] [Abstract][Full Text] [Related]
13. EHD1 confers resistance to cisplatin in non-small cell lung cancer by regulating intracellular cisplatin concentrations.
Gao J; Meng Q; Zhao Y; Chen X; Cai L
BMC Cancer; 2016 Jul; 16():470. PubMed ID: 27411790
[TBL] [Abstract][Full Text] [Related]
14. FAM60A promotes cisplatin resistance in lung cancer cells by activating SKP2 expression.
Hou Q; Jiang Z; Li Y; Wu H; Yu J; Jiang M
Anticancer Drugs; 2020 Sep; 31(8):776-784. PubMed ID: 32796403
[TBL] [Abstract][Full Text] [Related]
15. Effect of Nano-Platinum on Proliferation and Apoptosis of Non-Small Cell Lung Cancer Cells via P53 Pathway.
Liu Y; Hu F; Zhao L
J Nanosci Nanotechnol; 2021 Feb; 21(2):903-908. PubMed ID: 33183422
[TBL] [Abstract][Full Text] [Related]
16. Annexin A2 contributes to cisplatin resistance by activation of JNK-p53 pathway in non-small cell lung cancer cells.
Feng X; Liu H; Zhang Z; Gu Y; Qiu H; He Z
J Exp Clin Cancer Res; 2017 Sep; 36(1):123. PubMed ID: 28886730
[TBL] [Abstract][Full Text] [Related]
17. Hyper-O-GlcNAcylation induces cisplatin resistance via regulation of p53 and c-Myc in human lung carcinoma.
Luanpitpong S; Angsutararux P; Samart P; Chanthra N; Chanvorachote P; Issaragrisil S
Sci Rep; 2017 Sep; 7(1):10607. PubMed ID: 28878262
[TBL] [Abstract][Full Text] [Related]
18. Effects of VBMDMP on the reversal of cisplatin resistance in human lung cancer A549/DDP cells.
Wang CK; Zhang Y; Zhang ZJ; Qiu QW; Cao JG; He ZM
Oncol Rep; 2015 Jan; 33(1):372-82. PubMed ID: 25394854
[TBL] [Abstract][Full Text] [Related]
19. The 3p21.3 tumor suppressor RBM5 resensitizes cisplatin-resistant human non-small cell lung cancer cells to cisplatin.
Li P; Wang K; Zhang J; Zhao L; Liang H; Shao C; Sutherland LC
Cancer Epidemiol; 2012 Oct; 36(5):481-9. PubMed ID: 22609235
[TBL] [Abstract][Full Text] [Related]
20. miR-202 Enhances the Anti-Tumor Effect of Cisplatin on Non-Small Cell Lung Cancer by Targeting the Ras/MAPK Pathway.
Sun W; Ping W; Tian Y; Zou W; Liu J; Zu Y
Cell Physiol Biochem; 2018; 51(5):2160-2171. PubMed ID: 30522099
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
